Neonatal Respiratory Distress Syndrome
- Fetal Lung Immaturity
- Lack of Surfactant
- Respiratory Distress
- Nasal Flaring
- Retractions
- Grunting
- Surfactant
- Oxygen
- Mechanical Ventilation
- Total Parenteral Nutrition (TPN)
Cystic Fibrosis Mechanisms
- Autosomal Recessive
- CFTR Chromosome 7
- Cl- channel Defect
- Decreased Chloride Secretion
- Increased Na and Water Reabsorption
- Increased Na and Cl in Sweat
- Dehydration of Mucous Layers
Cystic Fibrosis Symptoms and Complications
- Recurrent Pulmonary Infections
- Chronic Bronchitis
- Nasal Polyps
- Pancreatic Insufficiency
- Intestinal Obstruction
- Malabsorption and Diarrhea
- Vitamin Deficiencies
- Chronic Hepatic Disease
- Infertility in Males
Cystic Fibrosis Diagnosis and Treatment
- Sweat Chloride Test > 60 mmol/L
- Meconium Ileus
- N-acetylcysteine
- Antibiotic Prophylaxis
- Pulmonary Maintenance
- Lung Transplant
- Vitamin Replacement
Asthma
- Obstructive lung disease
- Bronchial Hyperresponsiveness
- History of Atopic Disease
- Beta2 agonists
- Corticosteroids
- Curschmann's spirals
- Hypertrophy of smooth muscle
- Reversible
- Charcot Leyden crystals
- Methacholine challenge
- Wheezing
- Cough
- Initially decreased PaCO2
- Pulsus paradoxus
Intermittent Asthma
- Symptoms (Bronchoconstriction) and Rescue Inhaler Use ≤ 2 / Week
- No Interference With ADLs
- Nighttime Awakening < 2 / Month
- > 80 % of Predicted FEV1
Persistent Mild Asthma
- Symptoms (Brochoconstriction) and Rescue Inhaler Use > 2 Days / Week
- Nighttime Awakening 3-4 / Month
- Greater or equal to 80 % of Predicted FEV1
Persistent Moderate Asthma
- Symptoms (Bronchoconstriction) and Rescue Inhaler Use Daily
- Nighttime Awakening > 1 / Week
- 60-80% Predicted FEV1
- FEV1/FVC Decreased 5%
Persistent Severe Asthma
- Symptoms (Bronchoconstriction) and Rescue Inhaler Use: Multiple/ Day
- With Minimal Activity
- Nighttime Awakening: Nightly
- < 60% Predicted FEV1
- > 5% Decrease FEV1/FVC
Stages of Asthma Treatments
- Short-acting Inhaled Beta-Agonist
- Low-Dose Inhaled Corticosteroid
- Montelukast (Leukotriene Receptor Antagonist)
- Low to Medium-dose Inhaled Corticosteroid
- Zileuton
- High-Dose Inhaled Corticosteroid
- Systemic Corticosteroids
- Omalizumab (Allergies)
Croup (Laryngotracheobronchitis)
- Parainfluenza Virus
- 3 Months to 3 Years
- Nighttime
- Barking Seal Cough
- Inspiratory Stridor
- Cool Humidified Air
- Dexamethasone
- Racemic Epinephrine
Respiratory Syncytial Virus (RSV) Assessment
- Viral Infection Affecting Epithelial Cells
- Begins After a Upper Respiratory Infection
- Copious Secretions
- Coughing and Sneezing
- Wheezing
- Otitis Media or Conjunctivitis (Possible Ear or Eye Drainage)
- Poor Feeding
- Tachypnea
Respiratory Syncytial Virus (RSV) Interventions
- Palivizumab (Synagis)
- Hospitalization
- Contact Precautions
- Oxygen
- Separate Room
- Maintain Fluid Intake
- Short-acting Beta-Agonist Bronchodilator
Tracheoesophageal Fistula (TEF)
- Esophageal Atresia
- Ends in Blind Pouch
- Coughing
- Choking
- Cyanosis
- Drooling
- NPO
- Surgical Emergency
- Aspiration Pneumonia
Corynebacterium diphtheriae
- Gram-Positive
- Bacillus
- Exotoxin
- ADP Ribosylation of Elongation Factor 2
- Beta Prophage
- Lysogeny
- Tellurite Agar
- Chinese Letters
- Metachromatic Blue Red Granules
- Aniline Stains Deeply Methylene Blue
- Pseudomembranous Pharyngitis
- Lymphadenopathy
- Myocarditis
- Polyneuritis
Bordetella pertussis
- Gram-Negative
- Coccobacillus
- Bordet-Gengou Agar
- ADP Ribosylating AB Toxin
- Inhibits Gi to cause Increase in cAMP
- Lymphocytosis
- Increase in Insulin
- Catarrhal Phase is Infectious Period
- Paroxysmal Phase is Symptomatic Period
- Whooping Cough
- Macrolides
Influenza Virus
- RNA Virus
- Orthomyxovirus
- Enveloped
- Negative Sense
- 8 Segments
- Helical
- Hemagglutinin for Viral Entry
- Neuraminidase for Virion Release
- Genetic Shift
- Reassortment of genome to cause major change
- Genetic Drift
- Minor Antigenic Mutations
- Reye Syndrome with Aspirin Use
- Guillain-Barre Syndrome